Hidehito HORINOUCHI· @HHorinouchi · X·· 22 小时前评分70
正文 · 机器翻译
🆙#ESMO26 口头报告 I：#LCSM 转移
🔥OptiTROP-Lung06：Sacituzumab Tirumotecan (Sac-TMT) 联合 Pembrolizumab (P) 与 化疗 (Chemo) 联合 Pembrolizumab (P) 作为 PD-L1 阴性晚期非鳞状 (Nsq) NSCLC 一线 (1L) 治疗的随机 III 期研究
🎙️Dr. Caicun Zhou
🔢LBA66
🎯达到主要终点：BICR-PFS 15.0 对 5.7 个月 (HR 0.49, p<0.0001; n=455)
🎯OS 数据不成熟，呈有利趋势 (HR 0.58)
🎯≥3 级 TEAEs 47.6% 对 60.6%；≥3 级口炎 2.2%
☑️NCT06711900
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/272
@OncoAlert @Larvol @myESMO @IASLC
46 浏览 · 0 赞 · 0 转发 · 0 回复
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung06: Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab (P) Versus Chemotherapy (Chemo) Plus Pembrolizumab (P) as First-Line (1L) Treatment for PD-L1-Negative Advanced Non-Squamous (Nsq) NSCLC: Randomized Phase 3 Study 🎙️Dr. Caicun Zhou 🔢LBA66 🎯Met Primary Endpoint: BICR-PFS 15.0 vs 5.7mo (HR 0.49, p<0.0001; n=455) 🎯OS Immature, Favorable Trend (HR 0.58) 🎯Grade≥3 TEAEs 47.6% vs 60.6%; Grade≥3 Stomatitis 2.2% ☑️NCT06711900 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/272 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com